Shaily Engineering Plastics Limited — PPTs, 13-05-2025: Investor Presentation

1. Financial Highlights:

Shaily Engineering Plastics posted consolidated revenues of Rs. 787 Cr in FY25, up 22% YoY, with Q4 revenues at Rs. 218 Cr (+28% YoY). Gross margin improved by 470 bps to 47.2%, driving EBITDA up 45% to Rs. 178 Cr (margin 22.7%). PAT surged 63% to Rs. 93 Cr (margin 11.8%), with Cash PAT rising 45% to Rs. 135 Cr. Standalone results showed revenues of Rs. 738 Cr (+20%), EBITDA up 49% to Rs. 151 Cr, and PAT doubling to Rs. 71 Cr. RoCE strengthened to 24.4%, backed by lower debt/equity and higher fixed asset turnover, while rising inventories and receivables align with growth trends.

2. Strategic Initiatives & Growth Drivers:

Capacity expansion is in progress for pen manufacturing tied to commercial supplies of GLP-1 drug ‘Semaglutide’ from FY26. The company is ramping its IP-led pen platform with new customer additions and aggressively participating in pharma and packaging expos across key global markets. New product launches in plastics, carbon steel furniture, and automotive components aim to diversify revenue streams.

3. Business Developments:

Shaily secured six new contracts for pen injectors focused on chronic therapies during FY25 and won multiple awards from global retail chains and FMCG clients for its plastic and steel offerings. The company confirmed expansion into automotive components with new marquee customers in both FY25 and Q4.

4. Market Position & Competitive Advantage:

As India’s largest plastics exporter, Shaily benefits from a diversified portfolio spanning consumer, healthcare, and industrial sectors. Its scale—with 200+ injection molding machines and 7 automated facilities—drives operational flexibility. Deep global relationships and strong tech capabilities position it well in complex pharma and specialty packaging markets.

5. Investor Implications:

Robust revenue and margin gains, along with strong cash flow and strategic capacity scaling, point to positive growth potential. A diversified client mix mitigates concentration risk. Key execution areas to watch include capacity ramp-up and new contract fulfillment. Improving operating leverage and RoCE underscore enhanced capital efficiency and shareholder value creation.